期刊
MOLECULES
卷 22, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/molecules22101551
关键词
MEK inhibitors; targeted therapy; combination; approved drug; clinical study; preclinical study
资金
- Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, and Fundamental Research Fund for CAMSPUMC [2016ZX310199, 1649]
- CAMS Innovation Fund for Medical Sciences (CIFMS) from Chinese Academy of Medical Sciences & Peking Union Medical College [2017-I2M-3-019]
The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据